Priothera Ltd. today announces that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company’s Investigational New Drug (IND) application to begin its pivotal Phase 2b/3 study of mocravimod (named MO-TRANS). Priothera will initiate the MO-TRANS global Phase 2b/3 study in Europe, US and Japan, assessing the efficacy and safety…

eTurboNews članci su samo za pretplatnike. Pretplata je BESPLATNO.
Pretplatnici se prijavljuju ovdje Kliknite ovdje da se pretplatite BESPLATNO

ŠTO ISKLJUČITI IZ OVOG ČLANKA:

Priothera will initiate the MO-TRANS global Phase 2b/3 study in Europe, US and Japan, assessing the efficacy and safety….
Food and Drug Administration (FDA) has provided clearance to proceed with the Company’s Investigational New Drug (IND) application to begin its pivotal Phase 2b/3 study of mocravimod (named MO-TRANS).
today announces that the U.